HK1149567A1 - - Google Patents

Info

Publication number
HK1149567A1
HK1149567A1 HK11103609.4A HK11103609A HK1149567A1 HK 1149567 A1 HK1149567 A1 HK 1149567A1 HK 11103609 A HK11103609 A HK 11103609A HK 1149567 A1 HK1149567 A1 HK 1149567A1
Authority
HK
Hong Kong
Prior art keywords
ifn
antibodies
iddm
sle
subtypes
Prior art date
Application number
HK11103609.4A
Other languages
English (en)
Inventor
Anan Chuntharapai
Jin K Kim
Leonard G Presta
Timothy Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1149567A1 publication Critical patent/HK1149567A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/56—IFN-alpha
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
HK11103609.4A 2001-02-22 2011-04-11 HK1149567A1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27077501P 2001-02-22 2001-02-22
US10/044,896 US7087726B2 (en) 2001-02-22 2002-01-09 Anti-interferon-α antibodies

Publications (1)

Publication Number Publication Date
HK1149567A1 true HK1149567A1 (xx) 2011-10-07

Family

ID=26722123

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11103609.4A HK1149567A1 (xx) 2001-02-22 2011-04-11
HK11108154.2A HK1153967A1 (en) 2001-02-22 2011-08-04 Anti interferon alpha antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11108154.2A HK1153967A1 (en) 2001-02-22 2011-08-04 Anti interferon alpha antibodies

Country Status (19)

Country Link
US (8) US7087726B2 (xx)
EP (5) EP2305714A3 (xx)
JP (3) JP4384853B2 (xx)
KR (5) KR20120137512A (xx)
CN (3) CN102993303A (xx)
AT (1) ATE534739T1 (xx)
AU (3) AU2002306432B2 (xx)
CA (1) CA2437161C (xx)
CY (2) CY1112385T1 (xx)
DK (2) DK2065467T5 (xx)
ES (3) ES2461148T3 (xx)
HK (2) HK1149567A1 (xx)
IL (2) IL157170A0 (xx)
MX (1) MXPA03007529A (xx)
NZ (1) NZ527338A (xx)
PT (2) PT2065467E (xx)
RU (1) RU2314317C2 (xx)
SI (2) SI1362105T1 (xx)
WO (1) WO2002066649A2 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006100A (es) * 2001-01-09 2005-02-14 Baylor Reserch Inst Metodos para tratar enfermedades auto inmunes en un sujeto y examenes de diagnostico en tubo de ensayo.
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002343481A1 (en) * 2001-10-05 2003-04-22 Mount Sinais School Of Medecine Of New York University A hybrid fusion protein transcription regulator to induce interferon target gene expression
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
US7939076B2 (en) * 2003-04-23 2011-05-10 Medarex, Inc. Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
SI1711207T1 (sl) 2003-12-10 2013-07-31 Medarex, L.L.C Protitelesa interferona alfa in njihova raba
AU2012203451B2 (en) * 2003-12-10 2014-06-12 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
WO2006002177A2 (en) * 2004-06-21 2006-01-05 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
AU2005291741B2 (en) * 2004-10-07 2011-11-24 Universitat Zurich Type I interferon blocking agents for prevention and treatment of psoriasis
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
BRPI0607490A2 (pt) * 2005-02-10 2009-09-08 Baylor Res Inst anticorpos monoclonais antiinterferon alfa e métodos para uso
US20140154239A1 (en) * 2012-12-05 2014-06-05 Jacques Banchereau Anti-interferon alpha monoclonal antibodies and methods for use
JP2008543335A (ja) * 2005-06-22 2008-12-04 ジェネンテック・インコーポレーテッド Ｉｆｎａｒ２を標的とするための方法と組成物
US7767799B2 (en) 2005-06-29 2010-08-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Nucleic acid molecules encoding recombinant interferon-α2 (IFNα2) mutants
ES2462526T3 (es) 2006-04-24 2014-05-23 Genentech, Inc. Métodos y composiciones para detectar trastornos autoinmunitarios
JP5230022B2 (ja) * 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
AU2007327993B2 (en) * 2006-12-06 2013-06-20 Medimmune, Llc. Methods of treating systemic lupus erythematosus
EP2703007A1 (en) * 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
JP5411129B2 (ja) * 2007-05-03 2014-02-12 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
MX2010004814A (es) 2007-11-05 2010-08-10 Medimmune Llc Metodos para tratar esclerodermia.
CA2714410A1 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
EP2254998B1 (en) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
US8357782B2 (en) 2008-03-21 2013-01-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Monoclonal antibodies specific for human interferon-alpha subtype alpha 8
RU2532832C2 (ru) 2008-05-07 2014-11-10 Аргос Терапьютикс, Инк. Гуманизированные антитела против альфа-интерферона человека
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1
NZ607547A (en) 2010-09-01 2015-06-26 Univ Jefferson Composition and method for muscle repair and regeneration
AU2012249601A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR20140043402A (ko) * 2011-05-25 2014-04-09 메디뮨 엘엘씨 인터페론-알파에 대한 항체를 사용하여 전신홍반루푸스, 피부경화증 및 근육염을 치료하는 방법
WO2013059299A1 (en) * 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN102608328A (zh) * 2012-03-06 2012-07-25 无锡市普生生物工程技术有限公司 一种小鼠α干扰素的时间分辨荧光免疫分析试剂盒及其检测方法
MX366124B (es) * 2013-03-15 2019-06-27 Janssen Biotech Inc Anticuerpos antagonistas del interferón alfa y omega.
CN103484434A (zh) * 2013-06-28 2014-01-01 朱艮苗 杂交瘤细胞株及其应用
EP4056591A1 (en) * 2013-07-03 2022-09-14 ImmunoQure AG Human anti-ifn-alpha antibodies
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CN103592441B (zh) * 2013-10-29 2015-06-17 王明丽 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016112497A1 (zh) * 2015-01-13 2016-07-21 中国人民解放军军事医学科学院生物工程研究所 人源抗人α干扰素抗体及其应用
AU2016337598B2 (en) * 2015-10-15 2022-10-13 Biocon Limited Method for detecting neutralizing antibodies against recombinant human insulin in human serum
US10279565B2 (en) 2016-02-11 2019-05-07 Guardian Glass, LLC Vacuum insulating glass window unit including edge seal and/or method of making the same
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11202001311VA (en) 2017-08-22 2020-03-30 Sanabio Llc Soluble interferon receptors and uses thereof
BR112021015596A2 (pt) 2019-02-15 2021-10-05 Astrazeneca Ab Distúrbios mediados pelo interferon tipo i
WO2020202106A1 (en) * 2019-04-04 2020-10-08 Janssen Biotech, Inc. Method of administration of an anti-ifn-alpha/-omega antibody
CN116063487B (zh) * 2022-10-19 2023-08-29 武汉爱博泰克生物科技有限公司 抗人干扰素α2的兔单克隆抗体及其应用

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279547C (xx)
DD265291A (xx)
DE279317C (xx)
DE283154C (xx)
DE279548C (xx)
DE279546C (xx)
DE254593C (xx)
DE277087C (xx)
DE279266C (xx)
DE265291C (xx)
GB1160544A (en) 1965-06-10 1969-08-06 Reginald Frank Milton Method and apparatus for Preventing Condensation
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IN150740B (xx) 1978-11-24 1982-12-04 Hoffmann La Roche
US6410697B1 (en) 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
FI77877C (fi) 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0050129B1 (en) 1980-04-11 1992-03-18 Celltech Limited Monoclonal antibody
US4423147A (en) 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
WO1982001773A1 (en) 1980-11-07 1982-05-27 Secher David S Assay for interferon
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU561649B2 (en) 1981-02-27 1987-05-14 F. Hoffmann-La Roche Ag Antibodies to proteins
US4824432A (en) 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
DE3211263A1 (de) 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0085693A1 (en) 1981-08-14 1983-08-17 A/S Alfred Benzon Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies
JPS5835122A (ja) 1981-08-24 1983-03-01 Otsuka Pharmaceut Co Ltd 抗原の製造法
JPS5835124A (ja) 1981-08-24 1983-03-01 Otsuka Pharmaceut Co Ltd 抗体の製造法
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
JPS58225028A (ja) 1982-06-25 1983-12-27 Otsuka Pharmaceut Co Ltd ヒトα型インターフェロン抗体
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
JPS60500864A (ja) * 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8322310D0 (en) 1983-08-18 1983-09-21 Fujisawa Pharmaceutical Co Monoclonal antibodies
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
FR2560212B1 (fr) 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
JPS6113156A (ja) 1984-06-28 1986-01-21 Sumitomo Chem Co Ltd ヒトインタ−フエロン−αの定量用試薬及び定量法
JPS6172722A (ja) 1984-09-19 1986-04-14 Nippon Sekijiyuujishiya 抗インタ−フエロン単クロ−ン抗体及び同抗体を用いたヒト白血球インタ−フエロンの精製法
DD231007A1 (de) 1984-10-01 1985-12-18 Adw Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes interferon-alpha (huifn)
JPS6199828A (ja) 1984-10-22 1986-05-17 Sumitomo Electric Ind Ltd 微小温度測定装置
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS61225136A (ja) 1985-03-28 1986-10-06 Yamasa Shoyu Co Ltd マウスインタ−フエロンαに対するモノクロ−ナル抗体
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
KR880001757B1 (ko) 1985-10-02 1988-09-12 제일제당 주식회사 알파 인터페론 정제에 효과가 있는 단일항체의 제조방법
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DD279546A1 (de) 1986-06-17 1990-06-06 Akad Wissenschaften Ddr Verfahren zur immunaffinitaetschromatographischen reinigung von human-alpha-interferonen
GB8615353D0 (en) 1986-06-24 1986-07-30 Antibioticos Sa Interferon
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4795477A (en) 1986-07-16 1989-01-03 Celanese Corporation Printable polyacetal compositions
DE3633323A1 (de) 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DD279548A1 (de) 1986-10-15 1990-06-06 Akad Wissenschaften Ddr Verfahren zur quantitativen bestimmung von human-interferon-alpha-1
DD279547A1 (de) 1986-10-15 1990-06-06 Akad Wissenschaften Ddr Immunenzymometrisches bestimmungsverfahren fuer den quantitativen nachweis von human-interferon-alpha-2
GB8625480D0 (en) 1986-10-24 1986-11-26 Thomas J M Length measuring device
JPS63142000A (ja) 1986-12-04 1988-06-14 Meiji Seika Kaisha Ltd モノクロナ−ル抗体
DD254593A1 (de) 1986-12-15 1988-03-02 Adw Ddr Verfahren zur herstellung monoklonaler antikoerper gegen humanes interferon-alpha
KR920000051B1 (ko) 1987-01-12 1992-01-06 제일제당 주식회사 재조합 α-인터페론의 정제방법
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
EP0332084B1 (en) 1988-03-05 1993-06-23 Ohi Seisakusho Co., Ltd. Air spoiler retracting device
CS267392B1 (en) 1988-07-22 1990-02-12 Kontsek Peter Mouse lymphocytar hybridom vu ifn al 6
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6747131B1 (en) 1988-10-28 2004-06-08 Pestka Biomedical Laboratories, Inc. Phosphorylated fusion proteins
US6150503A (en) 1988-10-28 2000-11-21 Pestka Biomedical Laboratories, Inc. Phosphorylated fusion proteins
DD277087A1 (de) 1988-11-21 1990-03-21 Adw Ddr Verfahren zur gewinnung von neutralisierenden monoklonalen antikoerpern gegen humanes interferon-alpha
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5073491A (en) 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DD279266A1 (de) 1989-01-02 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes interferon-alpha-1 (huifn-alpha-1)
DD279317A1 (de) 1989-01-02 1990-05-30 Akad Wissenschaften Ddr Testbesteck zur immunenzymometrischen bestimmung von human-interferon-alpha-1
DD283154A5 (de) 1989-05-10 1990-10-03 Adw Ddr Verfahren zur herstellung monoklonaler antikoerper gegen humanes interferon-alpha 1
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
JP2888443B2 (ja) 1989-12-07 1999-05-10 日本ケミカルリサーチ株式会社 ヒト白血球インターフェロン亜種の抗体の製造法及び測定法
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2657881A1 (fr) 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
JP2808794B2 (ja) 1990-02-22 1998-10-08 ソニー株式会社 両面光ディスク
SU1756349A1 (ru) 1990-03-23 1992-08-23 Институт Микробиологии И Вирусологии Им.Д.К.Заболотного Штамм бактерий СоRYNевастеRIUм SереDоNIсUм - продуцент полисахарида, индуцирующего образование интерферона
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
JPH0477431A (ja) 1990-07-19 1992-03-11 Kanebo Ltd インターフェロン誘起剤
US5071762A (en) 1990-08-13 1991-12-10 Phillips Petroleum Company Enhancing the flavor of protein products derived from microorganisms
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CS276204B6 (en) 1990-10-22 1992-04-15 Virologicky Ustav Sav Mouse hybridoma ifna1-118 producing monoclonal antibody binding the human interferon alpha 1
CS276203B6 (en) 1990-10-22 1992-04-15 Virologicky Ustav Sav Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69324671D1 (de) 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
DE4216200A1 (de) 1992-05-15 1993-11-18 Max Delbrueck Centrum Verfahren zur Herstellung von monoklonalen Antikörpern gegen humanes Interferon-alpha-2
JPH0650971A (ja) 1992-05-27 1994-02-25 Takeda Chem Ind Ltd ヒトインターフェロンαの免疫学的測定法およびその試薬
CZ4038U1 (cs) 1992-08-28 1995-10-30 Miroslav Šafek Elektrický soklový konvektor
IL108584A (en) * 1994-02-07 2008-03-20 Yeda Res & Dev Cloning of the interferon-binding protein ALPHA / BETA
WO1995013539A1 (fr) 1992-09-30 1995-05-18 Daiichi Pure Chemicals Co., Ltd. Methode de dosage d'anticorps anti-interferon et reactif utilise dans ce dernier
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5626843A (en) 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
US6299870B1 (en) 1993-06-11 2001-10-09 Pbl Biomedical Laboratories Mutant human interferons
EP0751955A4 (en) 1993-06-11 1998-10-07 Pestka Biomedical Lab Inc SUPER PROTEINS COMPRISING INTERFERONS AND INTERLEUKINS
US6001589A (en) 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
DE69408541T2 (de) 1993-11-23 1998-08-06 Genentech Inc Kinaserezeptoraktivierungstest
JP4001379B2 (ja) * 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU2466895A (en) * 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6433145B1 (en) 1998-07-21 2002-08-13 Human Genome Sciences, Inc. Keratinocyte derived interferon
CN1214043C (zh) * 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
EP1141299A2 (en) 1998-12-23 2001-10-10 Genentech, Inc. Il-1 related polypeptides
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6312924B1 (en) 1999-03-18 2001-11-06 Zymogenetics, Inc. Murine interferon-α
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
WO2002006329A2 (en) 2000-07-18 2002-01-24 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
IL155741A0 (en) 2000-11-03 2003-12-23 Pbl Biomedical Lab Interferons, uses and compositions related thereto
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
US6580843B2 (en) 2001-04-05 2003-06-17 Fujitsu Limited Optical device
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2825102B1 (fr) 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
FR2825716B1 (fr) 2001-06-11 2004-09-24 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
US6860645B2 (en) 2003-06-26 2005-03-01 Furukawa Electric North America, Inc. Optical fiber cable connector assembly with strain relief
US9109133B2 (en) 2012-04-19 2015-08-18 Seiko Epson Corporation Ink jet ink and recorded object

Also Published As

Publication number Publication date
KR20090107095A (ko) 2009-10-12
IL157170A (en) 2010-11-30
EP2065467B9 (en) 2014-04-23
US20030166228A1 (en) 2003-09-04
CN101857636A (zh) 2010-10-13
IL157170A0 (en) 2004-02-08
ES2461148T3 (es) 2014-05-16
JP4384853B2 (ja) 2009-12-16
MXPA03007529A (es) 2003-12-11
US8557967B2 (en) 2013-10-15
CN101857636B (zh) 2012-10-10
US7087726B2 (en) 2006-08-08
WO2002066649A2 (en) 2002-08-29
EP2292301A3 (en) 2012-03-07
ATE534739T1 (de) 2011-12-15
JP2012245008A (ja) 2012-12-13
WO2002066649A3 (en) 2003-04-03
AU2011200707B2 (en) 2013-06-20
US20070059309A1 (en) 2007-03-15
US20130309236A1 (en) 2013-11-21
ES2378062T3 (es) 2012-04-04
JP5349018B2 (ja) 2013-11-20
EP2301629A3 (en) 2012-05-02
US20110268727A1 (en) 2011-11-03
CA2437161C (en) 2016-06-07
HK1153967A1 (en) 2012-04-13
US7582445B2 (en) 2009-09-01
US20130084295A1 (en) 2013-04-04
AU2002306432C9 (en) 2002-09-04
EP2292301B1 (en) 2014-03-12
EP2305714A2 (en) 2011-04-06
CY1114901T1 (el) 2016-12-14
RU2314317C2 (ru) 2008-01-10
CN1492930A (zh) 2004-04-28
KR20100095641A (ko) 2010-08-31
KR101413907B1 (ko) 2014-06-30
EP1362105B1 (en) 2011-11-23
US20070048311A1 (en) 2007-03-01
CN102993303A (zh) 2013-03-27
DK2065467T5 (da) 2014-06-30
AU2011200707A1 (en) 2011-03-10
US8349331B2 (en) 2013-01-08
CA2437161A1 (en) 2002-08-29
RU2003128365A (ru) 2005-01-20
JP2004533217A (ja) 2004-11-04
AU2002306432C1 (en) 2002-09-04
PT1362105E (pt) 2012-02-28
DK2065467T3 (da) 2013-11-25
US7910707B2 (en) 2011-03-22
KR20030081461A (ko) 2003-10-17
US20120244148A1 (en) 2012-09-27
SI1362105T1 (sl) 2012-03-30
AU2002306432B2 (en) 2006-09-14
NZ527338A (en) 2006-08-31
KR20110066232A (ko) 2011-06-16
EP2065467A3 (en) 2009-09-02
EP2301629A2 (en) 2011-03-30
CY1112385T1 (el) 2015-12-09
KR100940968B1 (ko) 2010-02-08
DK1362105T3 (da) 2012-03-12
EP1362105A2 (en) 2003-11-19
ES2436787T3 (es) 2014-01-07
SI2065467T1 (sl) 2014-01-31
US20110206663A1 (en) 2011-08-25
KR20120137512A (ko) 2012-12-21
KR101154643B1 (ko) 2012-06-08
EP2065467B1 (en) 2013-10-23
EP2305714A3 (en) 2012-03-28
EP2292301A2 (en) 2011-03-09
JP2009131257A (ja) 2009-06-18
AU2006252117A1 (en) 2007-01-11
WO2002066649A8 (en) 2002-10-17
EP2065467A2 (en) 2009-06-03
PT2065467E (pt) 2014-01-23

Similar Documents

Publication Publication Date Title
HK1149567A1 (xx)
WO2005115437A3 (en) Methods for affecting body composition
EP2292661A3 (en) Interleukin-10 antibodies
ATE540035T1 (de) Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
WO2006072068A3 (en) Dynamic splint assembly
EP1571548A3 (en) Hosted application as a designer in an integrated development environment
WO2003045228A3 (en) Methods for treating autoimmune disorders, and reagents related thereto
AU2003263932A1 (en) Silicone elastomers compositions
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
EP1676885A3 (en) Elastomer composition and molded body
WO2003058353A3 (en) Watch light
WO2007073243A3 (en) Method and device for unpacking a condom
WO2005006714A3 (en) Carabiner communication device
AU2004208906A8 (en) Suit for use in or on water
EP2292666A3 (en) Neoplasm specific antibodies and uses thereof
GB2430136A (en) Personal accessory carrier
WO2005062893A3 (en) Anti-cd52 antibody treatment for diabetes
Cantera Hair-saving unhairing process. Part 2. Immunization phenomenon
WO2004031767A3 (en) Prevention of primary sjögren’s syndrome by ica69 deficiency
TW200507889A (en) Silicone hydrogels having consistent concentrations of multifunctional polysiloxanes
Jeff et al. Mass bounds in a model with a triplet Higgs
Chung et al. Effects of gender and emotional expression of anthropomorphic interface agent on users' perception of the agent
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
UA28421A (uk) Комплект інструментарію для тестування фізичної підготовленості населення "супутник-1"
WO2000044273A3 (en) Diagnosis and prediction of light therapy response in seasonal affect disorder patients using g-protein subunit measurements

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220128